

In re Progenity Inc. Securities Litigation
c/o Strategic Claims Services
600 N. Jackson St., Ste. 205
Media, PA 19063

COURT-ORDERED LEGAL NOTICE

**Important Notice about a Securities
Class Action Settlement.**

**You may be entitled to a CASH
payment. This Notice may affect your
legal rights. Please read it carefully.**

In re Progenity Inc. Securities Litigation
Case No. 3:20-cv-01683

***THIS CARD PROVIDES ONLY LIMITED INFORMATION ABOUT THE SETTLEMENT.
PLEASE VISIT WWW.STRATEGICCLAIMS.NET/PROGENITY FOR MORE INFORMATION.***

There has been a proposed Settlement of claims against Progenity Inc. (“Progenity”) (n/k/a Biora Therapeutics, Inc.), certain underwriters of its initial public offering, and certain executives and directors of Progenity (collectively, the “Defendants”). The Settlement would resolve a lawsuit in which Plaintiffs allege that Defendants disseminated materially false and misleading information to the investing public about Progenity’s molecular testing business, in violation of the federal securities laws. Defendants deny any wrongdoing. You received this Postcard Notice because you or someone in your family may have purchased or otherwise acquired Progenity common stock pursuant and/or traceable to Progenity’s initial public offering Registration Statement (*i.e.*, from June 18, 2020 through December 2, 2020, both dates inclusive), and been damaged thereby.

Defendants, excluding Progenity which has filed for bankruptcy protection, have agreed to pay a Settlement Amount of \$1,000,000. The Settlement provides that the Settlement Fund, after deduction of any Court-approved attorneys’ fees and expenses, notice and administration costs, and taxes, is to be divided among all Settlement Class Members who submit a valid Claim Form, in exchange for the settlement of this case and the Releases by Settlement Class Members of claims related to this case. **For all details of the Settlement, read the Stipulation and Notice, available at www.strategicclaims.net/progenity.**

Your share of the Settlement proceeds will depend on the number of valid Claims submitted, and the number, size and timing of your transactions in Progenity common stock. If every eligible Settlement Class Member submits a valid Claim Form, the average recovery will be \$0.21 per eligible share of Progenity common stock before expenses and other Court-ordered deductions. Your award will be determined *pro rata* based on the number of claims submitted. This is further explained in the detailed Notice found on the Settlement website.

To qualify for payment, you must submit a Claim Form. The Claim Form can be found on the website www.strategicclaims.net/progenity or will be mailed to you upon request to the Claims Administrator by calling toll-free (866) 274-4004. **Claim Forms must be postmarked or submitted online by February 3, 2026.** If you do not want to be legally bound by the Settlement, you must exclude yourself by February 3, 2026, or you will not be able to sue the Defendants about the legal claims in this case. If you exclude yourself, you cannot get money from this Settlement. If you want to object to the Settlement, you may file an objection by February 3, 2026. The detailed Notice explains how to submit a Claim Form, exclude yourself, or object.

The Court will hold a hearing in this case on February 23, 2026, to consider whether to approve the Settlement and a request by the lawyers representing the Settlement Class for up to 33⅓% of the Settlement Fund in attorneys’ fees, plus actual expenses up to \$102,500 for litigating the case and negotiating the Settlement, and reimbursement of Plaintiffs’ costs and expenses related to their representation of the Settlement Class in an aggregate amount not to exceed \$7,500. You may attend the hearing and ask to be heard by the Court, but you do not have to. For more information, call toll-free (866) 274-4004 or visit the website www.strategicclaims.net/progenity and read the detailed Notice.